A Clinical Study of MIL93 in Solid Tumors.

NCT04671875 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

228

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancies

Interventions

DRUG: Recombinant Humanized Monoclonal Antibody MIL93

Sponsor

Beijing Mabworks Biotech Co., Ltd.